Holen Sie sich die Stockscreener-App
25.59
2.14%
-0.595
Schlusskurs vom Vortag:
$26.18
Offen:
$26.06
24-Stunden-Volumen:
329.41K
Relative Volume:
0.19
Marktkapitalisierung:
$5.16B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-382.71M
KGV:
-9.7653
EPS:
-2.62
Netto-Cashflow:
$-325.64M
1W Leistung:
-2.47%
1M Leistung:
-4.26%
6M Leistung:
+39.31%
1J Leistung:
+9.49%
1-Tages-Spanne:
$25.53
$26.60
1-Wochen-Bereich:
$25.43
$26.69
52-Wochen-Spanne:
$12.72
$27.80
Immunovant Inc Stock (IMVT) Company Profile
Firmenname
Immunovant Inc
Sektor
Branche
Telefon
917-580-3099
Adresse
320 WEST 37TH STREET, NEW YORK, NY
Vergleichen Sie IMVT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
25.59 | 5.27B | 0 | -382.71M | -325.64M | -2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.63 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.34 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.84 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-06 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-10-14 | Eingeleitet | Truist | Hold |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2025-03-03 | Eingeleitet | Jefferies | Hold |
| 2025-01-03 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-10-09 | Bestätigt | Oppenheimer | Outperform |
| 2024-03-28 | Eingeleitet | Oppenheimer | Outperform |
| 2024-03-13 | Eingeleitet | Goldman | Buy |
| 2024-02-20 | Eingeleitet | JP Morgan | Overweight |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-13 | Hochstufung | UBS | Neutral → Buy |
| 2023-09-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | Eingeleitet | BofA Securities | Buy |
| 2023-04-25 | Eingeleitet | Citigroup | Buy |
| 2023-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2023-03-30 | Eingeleitet | Stifel | Buy |
| 2023-02-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-01-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | Herabstufung | UBS | Buy → Neutral |
| 2021-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-08-03 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-06-01 | Herabstufung | Stifel | Buy → Hold |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-10-12 | Eingeleitet | Guggenheim | Buy |
| 2020-10-08 | Eingeleitet | Stifel | Buy |
| 2020-10-02 | Eingeleitet | Credit Suisse | Outperform |
| 2020-08-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-07-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-24 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Immunovant Inc Aktie (IMVT) Neueste Nachrichten
(IMVT) Volatility Zones as Tactical Triggers - Stock Traders Daily
Immunovant, Inc. (NASDAQ:IMVT) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
SG Americas Securities LLC Has $1.01 Million Stock Holdings in Immunovant, Inc. $IMVT - MarketBeat
Merger Talk: What are Immunovant Incs earnings expectationsTrade Risk Report & Precise Buy Zone Tips - baoquankhu1.vn
Assessing Immunovant (IMVT) Valuation After Strong 90 Day Share Price Momentum - Yahoo Finance
How Much Upside is Left in Immunovant (IMVT)? Wall Street Analysts Think 47.39% - Finviz
Immunovant (NASDAQ:IMVT) Stock Price Down 5.7%Should You Sell? - MarketBeat
Portfolio Update: Is Immunovant Inc stock gaining market share2025 Year in Review & Capital Efficient Trade Techniques - Bộ Nội Vụ
Truist lifts Immunovant (IMVT) PT to $22 on updated 2026 financial modeling - MSN
Truist Lifts Immunovant (IMVT) PT to $22 on Updated 2026 Financial Modeling - Insider Monkey
Sjogren’s Syndrome Market to Experience Notable Growth in Forecast Span by 2034, DelveInsight Predicts | Astellas Pharma, Immunovant Sciences, NK Cells Artiva Biotherapeutics, Rise Therapeutics - Barchart.com
Price-Driven Insight from (IMVT) for Rule-Based Strategy - Stock Traders Daily
10 Promising Stocks to Buy Under $50 - Insider Monkey
Immunovant announces $550 million stock offering - MSN
Immunovant CTO Stout sells $32k in IMVT stock By Investing.com - Investing.com Canada
Immunovant CTO Stout sells $32k in IMVT stock - Investing.com
Immunovant (NASDAQ:IMVT) CTO Jay Stout Sells 1,203 Shares - MarketBeat
Immunovant (NASDAQ:IMVT) Reaches New 52-Week High on Analyst Upgrade - MarketBeat
Immunovant stock hits 52-week high at $27.71 By Investing.com - Investing.com India
Immunovant stock hits 52-week high at $27.71 - Investing.com
Market Recap: Can Immunovant Inc. stock maintain operating marginsWeekly Investment Summary & Real-Time Market Sentiment Alerts - Улправда
How Immunovant Inc. stock compares to industry benchmarksJuly 2025 Gainers & Smart Swing Trading Alerts - Улправда
How Immunovant Inc. stock performs in stagflationPortfolio Risk Report & Precise Trade Entry Recommendations - ulpravda.ru
What technical charts say about Immunovant Inc. stockWeekly Risk Summary & Free Fast Gain Swing Trade Alerts - ulpravda.ru
Immunovant (NASDAQ:IMVT) Price Target Raised to $22.00 at Truist Financial - MarketBeat
Wolfe Research upgrades Immunovant stock to Outperform on Graves’ disease potential By Investing.com - Investing.com South Africa
Wolfe Research Upgrades Immunovant (IMVT) - Nasdaq
Wolfe Research upgrades Immunovant stock to Outperform on Graves’ disease potential - Investing.com Nigeria
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT) - PR Newswire
Immunovant CEO Peter Salzmann sells $208,899 in stock - MSN
Wolfe Research Downgrades Immunovant (IMVT) - MSN
(IMVT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Immunovant (NASDAQ:IMVT) Nasdaq Today Immunology Innovation - Kalkine Media
Immunovant, Inc. (NASDAQ:IMVT) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
How Investors Are Reacting To Immunovant (IMVT) $550 Million Follow-On Equity Raise And Dilution - Sahm
Assenagon Asset Management S.A. Invests $3.31 Million in Immunovant, Inc. $IMVT - MarketBeat
Research Analysts Issue Forecasts for Immunovant Q3 Earnings - MarketBeat
Momentum Shift: How Immunovant Inc. stock responds to policy changesChart Signals & Consistent Income Trade Recommendations - Улправда
How Immunovant Inc. stock compares to growth peers2025 Top Gainers & Technical Confirmation Alerts - Улправда
Squarepoint Ops LLC Has $1.36 Million Stock Position in Immunovant, Inc. $IMVT - MarketBeat
How Immunovant Inc. stock responds to policy changesInflation Watch & Long-Term Safe Return Strategies - ulpravda.ru
Tuyl Christopher Van Sells 10,813 Shares of Immunovant (NASDAQ:IMVT) Stock - MarketBeat
Officer Van Tuyl Acquires 16,676 Of Immunovant Inc [IMVT] - TradingView — Track All Markets
Immunovant Executive Sells Shares to Cover Tax Obligations - TradingView — Track All Markets
First Week of IMVT February 2026 Options Trading - Nasdaq
Can Immunovant Inc. stock weather global recessionPortfolio Growth Summary & Low Drawdown Investment Strategies - DonanımHaber
Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million? - AOL.com
Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million? - The Motley Fool
Share Offerings Prompt Huge Insider Buying in These 3 Biotechs - AOL.com
Finanzdaten der Immunovant Inc-Aktie (IMVT)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.38%
1.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):